Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Sold by Tompkins Financial Corp

Tompkins Financial Corp trimmed its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 1.7% in the second quarter, HoldingsChannel reports. The institutional investor owned 15,051 shares of the medical equipment provider’s stock after selling 253 shares during the period. Tompkins Financial Corp’s holdings in Intuitive Surgical were worth $5,147,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Covenant Asset Management LLC boosted its position in Intuitive Surgical by 483.1% during the 2nd quarter. Covenant Asset Management LLC now owns 11,994 shares of the medical equipment provider’s stock worth $4,101,000 after purchasing an additional 9,937 shares during the period. Windsor Group LTD boosted its position in Intuitive Surgical by 8.7% during the 2nd quarter. Windsor Group LTD now owns 1,685 shares of the medical equipment provider’s stock worth $576,000 after purchasing an additional 135 shares during the period. Burns J W & Co. Inc. NY boosted its position in Intuitive Surgical by 0.8% during the 2nd quarter. Burns J W & Co. Inc. NY now owns 6,436 shares of the medical equipment provider’s stock worth $2,201,000 after purchasing an additional 54 shares during the period. Darwin Wealth Management LLC purchased a new stake in Intuitive Surgical during the 2nd quarter worth $213,000. Finally, Bath Savings Trust Co boosted its position in Intuitive Surgical by 0.5% during the 2nd quarter. Bath Savings Trust Co now owns 14,723 shares of the medical equipment provider’s stock worth $5,034,000 after purchasing an additional 70 shares during the period. 82.91% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. Sanford C. Bernstein upped their price objective on shares of Intuitive Surgical from $350.00 to $365.00 in a research report on Wednesday, May 31st. Mizuho upped their target price on shares of Intuitive Surgical from $300.00 to $370.00 in a research note on Monday, July 17th. JPMorgan Chase & Co. upped their target price on shares of Intuitive Surgical from $335.00 to $365.00 and gave the company an “overweight” rating in a research note on Friday, July 21st. Robert W. Baird started coverage on shares of Intuitive Surgical in a research note on Tuesday, July 18th. They issued an “outperform” rating and a $377.00 target price on the stock. Finally, TheStreet upgraded shares of Intuitive Surgical from a “c+” rating to a “b” rating in a research note on Monday, July 24th. Five analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Intuitive Surgical currently has an average rating of “Moderate Buy” and an average target price of $343.10.

Insider Activity

In other news, EVP Robert Desantis sold 2,535 shares of the stock in a transaction that occurred on Tuesday, July 25th. The shares were sold at an average price of $323.26, for a total value of $819,464.10. Following the completion of the transaction, the executive vice president now directly owns 7,259 shares in the company, valued at $2,346,544.34. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, EVP Robert Desantis sold 2,535 shares of the stock in a transaction that occurred on Tuesday, July 25th. The shares were sold at an average price of $323.26, for a total value of $819,464.10. Following the completion of the transaction, the executive vice president now directly owns 7,259 shares in the company, valued at $2,346,544.34. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Alan J. Levy sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $310.00, for a total transaction of $620,000.00. Following the sale, the director now owns 25,319 shares of the company’s stock, valued at $7,848,890. The disclosure for this sale can be found here. Insiders sold 60,309 shares of company stock worth $19,649,321 over the last three months. Corporate insiders own 0.90% of the company’s stock.

Intuitive Surgical Stock Performance

Shares of NASDAQ:ISRG traded down $2.50 during trading hours on Tuesday, hitting $295.67. The stock had a trading volume of 144,239 shares, compared to its average volume of 1,693,164. The stock’s fifty day simple moving average is $314.56 and its 200 day simple moving average is $298.07. Intuitive Surgical, Inc. has a 1-year low of $180.07 and a 1-year high of $358.07. The firm has a market capitalization of $103.90 billion, a price-to-earnings ratio of 74.73, a PEG ratio of 4.15 and a beta of 1.30.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings results on Thursday, July 20th. The medical equipment provider reported $1.42 EPS for the quarter, beating the consensus estimate of $1.33 by $0.09. The company had revenue of $1.76 billion for the quarter, compared to analyst estimates of $1.74 billion. Intuitive Surgical had a net margin of 21.38% and a return on equity of 12.41%. Intuitive Surgical’s revenue was up 15.4% compared to the same quarter last year. During the same quarter last year, the business earned $0.85 earnings per share. As a group, research analysts anticipate that Intuitive Surgical, Inc. will post 4.53 EPS for the current year.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.